Tenaya Therapeutics (TNYA) investor relations material

Executive summary

• Advanced gene therapy and small molecule candidates for heart disease, with three clinical-stage programs (TN-201, TN-401, TN-301) and multiple early-stage pipeline programs.

• Positive interim data from MyPEAK-1 (TN-201) and RIDGE-1 (TN-401) trials showed meaningful improvements in key disease characteristics, with regulatory engagement ongoing for pivotal trial planning and updates expected in Q4 2026.

• Entered a multi-target research collaboration with Alnylam Pharmaceuticals, providing a $10 million upfront payment, research reimbursement, and potential milestones up to $1.1 billion.

• Decommissioned internal manufacturing facility and completed lease termination to reduce costs, transitioning to contract manufacturing.

• Appointment of new CFO effective July 13, 2026.

Financial highlights

• Collaboration revenue was $1.1 million for Q2 2026, up from $0 in Q2 2025, driven by new agreements.

• Net loss for Q2 2026 was $43.4 million ($0.20 per share), compared to $23.3 million ($0.14 per share) in Q2 2025, primarily due to a $21.8 million impairment loss and $1.4 million lease termination loss.

• Operating expenses rose 88% year-over-year to $45.2 million in Q2 2026, mainly due to impairment and lease termination losses.

• Research and development expenses decreased 4% year-over-year to $16.6 million in Q2 2026; G&A expenses were $5.4 million, down from $6.7 million.

• Cash and cash equivalents were $78.1 million as of June 30, 2026, including the Alnylam payment.

Outlook and guidance

• Existing cash and equivalents expected to fund operations through Q3 2027.

• Plans to present additional clinical data and regulatory updates for TN-201 and TN-401 in Q4 2026.

• Intends to initiate at least one Phase 2 proof-of-activity trial for TN-301 in 2H 2027.

• May seek additional capital through equity, debt, or partnerships to support late-stage development and commercialization.